F. Borsa-Lebas

发表

Successful treatment of metronidazole- and albendazole-resistant giardiasis with nitazoxanide in a patient with acquired immunodeficiency syndrome.

G. Gargala, J. Ballet, P. Abboud, 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Hepatitis B virus-human immunodeficiency virus co-infection in France: a cross-sectional multicentre study

S. Pol, D. Sène, P. Cacoub, 2006, Epidemiology and Infection.

Pharmacokinetics of quinolones in renal insufficiency.

J. Fillastre, B. Moulin, G. Humbert, 1990, The Journal of antimicrobial chemotherapy.

Les traitements courts de l'infection urinaire

F. Lecomte, F. Borsa-Lebas, G. Humbert, 1987 .

Comparison of activation marker and TCR Vβ gene product expression by CD4+ and CD8+ T cells in peripheral blood and lymph nodes from HIV‐infected patients

F. Tron, F. Michot, G. Humbert, 1995, Clinical and experimental immunology.

Therapeutic management and evolution of chronic hepatitis B: does HIV still have an impact? The EPIB 2012 study

F. Carrat, S. Pol, P. Cacoub, 2015, Liver international : official journal of the International Association for the Study of the Liver.

Pharmacokinetics of meropenem (ICI 194,660) and its metabolite (ICI 213,689) in healthy subjects and in patients with renal impairment

J. Fillastre, I. Étienne, G. Humbert, 1992, Antimicrobial Agents and Chemotherapy.

Pharmacokinetics of meropenem in subjects with renal insufficiency

J. Fillastre, I. Étienne, G. Humbert, 2004, European Journal of Clinical Pharmacology.

HIV-1 resistance genotyping on dried serum spots

F. Caron, V. Lemée, J. Plantier, 2005, AIDS.

Effects of ketoprofen (NSAID) on the pharmacokinetics of pefloxacin and ofloxacin in healthy volunteers.

J. Fillastre, I. Étienne, G. Humbert, 1992, Drugs under experimental and clinical research.

Importance of Baseline Prognostic Factors With Increasing Time Since Initiation of Highly Active Antiretroviral Therapy: Collaborative Analysis of Cohorts of HIV-1-Infected Patients

Anne M Johnson, A. Trkola, J. Sterne, 2007, Journal of acquired immune deficiency syndromes.

Urolithiasis in HIV-positive patients treated with atazanavir.

D. Neau, M. Daudon, C. Couzigou, 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

During HIV infection, CD4+ CD38+ T-cells are the predominant circulating CD4+ subset whose HLA-DR positivity increases with disease progression and whose V beta repertoire is similar to that of CD4+ CD38- T-cells.

F. Tron, D. Gilbert, G. Humbert, 1995, Clinical immunology and immunopathology.

F. Tron, D. Gilbert, G. Humbert, 1996 .

F. Tron, D. Gilbert, G. Humbert, 1996, Clinical immunology and immunopathology.

Maraviroc Intensification in HIV-1 Infected Patients with Persistant Low-levelViremia

E. Rouveix, C. Dupont, D. Mathez, 2016 .

[Salmonella typhimurium cerebral abscess in a patient with HIV infection].

F. Caron, G. Humbert, I. Gueit, 1996, Presse medicale.

Complicated atazanavir-associated cholelithiasis: a report of 14 cases.

P. Tattevin, C. Arvieux, E. Polard, 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Impact of Human Immunodeficiency Virus Type 1 Minority Variants on the Virus Response to a Rilpivirine-Based First-line Regimen

V. Calvez, C. Charpentier, F. Brun-Vézinet, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Pharmacologic Boosting of Atazanavir in Maintenance HIV-1 Therapy: The COREYA Propensity-Score Adjusted Study

Y. Yazdanpanah, J. Parienti, L. Hocqueloux, 2012, PloS one.